Literature DB >> 946131

Evidence for defective skeletal mineralization in low-birthweight infants: the absorption of calcium and fat.

J C Shaw.   

Abstract

Using serial metabolic balance techniques, the absorption and retention of calcium and the absorption of fat have beem measured over the first 30 to 70 days of life in 11 preterm and 2 full-term light-for-dates infants. They were fed either full-cream cow's milk, half-skimmed cow's milk, the proprietary filled milk S.M.A., or breast milk. The values for calcium intake, absorption and retention were compared with the rate of accumulation of calcium by the fetus in utero, which was calculated from published data on the chemical composition of fetal bodies. Infants fed breast milk had an absolute dietary deficiency of calcium. Those fed other milks ingested sufficient but they did not absorb enough. Though calcium absorption increased with increasing postnatal age, intrauterine rates of calcium retention were never achieved on any of the milks. The average retention of calcium by preterm infants as a percentage of intrauterine accumulation was, for cow's milk 38%, for S.M.A. 27%, and for breast milk 17%. The full-term light-for- dates infants absorbed and retained more calcium than the preterm infants; it was on average 52% of the amount accumulated by the human fetus for an equivalent weight gain. The average absorption of fat by preterm infants was, from the cow's milk preparations 55%, from S.M.A. 61%, and from breast milk 84%. The light-for-dates infants absorbed on average 87% of the breast milk fat. There was no evidence that the amount of calcium absorbed was materially influenced by fat malabsorption. The principal determinants of the amount of calcium absorbed were the length of gestation and postnatal age of the infant.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 946131

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  17 in total

Review 1.  Bone development in the fetus and neonate: role of the calciotropic hormones.

Authors:  Christopher S Kovacs
Journal:  Curr Osteoporos Rep       Date:  2011-12       Impact factor: 5.096

2.  Bone mineralisation in preterm infants measured by dual energy radiographic densitometry.

Authors:  A J Lyon; D J Hawkes; M Doran; N McIntosh; F Chan
Journal:  Arch Dis Child       Date:  1989-07       Impact factor: 3.791

3.  Bone cortical mass in newborn infants: a comparison between standards in the femur and humerus.

Authors:  J C Odita; A A Okolo; J A Omene
Journal:  Skeletal Radiol       Date:  1986       Impact factor: 2.199

Review 4.  Copper deficiency and non-accidental injury.

Authors:  J C Shaw
Journal:  Arch Dis Child       Date:  1988-04       Impact factor: 3.791

5.  Results of extremely-low-birth-weight infants randomized to receive extra enteral calcium supply.

Authors:  William F Carroll; Jorge Fabres; Tim R Nagy; Marcela Frazier; Claire Roane; Frank Pohlandt; Waldemar A Carlo; Ulrich H Thome
Journal:  J Pediatr Gastroenterol Nutr       Date:  2011-09       Impact factor: 2.839

6.  Fat as an energy supplement for preterm infants.

Authors:  O J Hanmer; W T Houlsby; H Thom; I S Ross; D J Lloyd; G Russell
Journal:  Arch Dis Child       Date:  1982-07       Impact factor: 3.791

7.  Metabolic bone disease in preterm infants.

Authors:  O G Brooke; A Lucas
Journal:  Arch Dis Child       Date:  1985-07       Impact factor: 3.791

8.  Serum calcitonin concentrations in premature infants during the first 12 weeks of life.

Authors:  L S Hillman; N Hoff; J Walgate; J G Haddad
Journal:  Calcif Tissue Int       Date:  1982-09       Impact factor: 4.333

9.  Calcium intake in the first five days of life in the low birthweight infant. Effects of calcium supplements.

Authors:  M Moya; E Doménech
Journal:  Arch Dis Child       Date:  1978-10       Impact factor: 3.791

10.  Reference values for urinary calcium and phosphorus to prevent osteopenia of prematurity.

Authors:  F Pohlandt; W A Mihatsch
Journal:  Pediatr Nephrol       Date:  2004-09-03       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.